Clinical Trial Detail

NCT ID NCT03535363
Title Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Case Comprehensive Cancer Center
Indications

lung non-small cell carcinoma

Therapies

Osimertinib

Age Groups: adult senior

No variant requirements are available.